Imugene
Sydney
About Imugene
Imugene is a clinical-stage immuno-oncology firm researching a variety of innovative medicines that aim to engage cancer patients' immune systems in order to find and eradicate tumors. OnCARlytics (CF33-CD19) is a novel and successful combination immunotherapy that uses the CF33 oncolytic virus to deliver and show CD19 antigen on the surface of cancer cells, enabling CD19 CAR T cell anti-tumor responses against solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $70.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2024)
- Ticker: asx:IMU
- Website: imugene.com
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/imugene-107546 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.